293 related articles for article (PubMed ID: 9469684)
1. Sertindole, a new atypical antipsychotic for the treatment of schizophrenia.
Brown LA; Levin GM
Pharmacotherapy; 1998; 18(1):69-83. PubMed ID: 9469684
[TBL] [Abstract][Full Text] [Related]
2. Sertindole: a review of clinical efficacy.
Kane JM
Int Clin Psychopharmacol; 1998 Mar; 13 Suppl 3():S59-63; discussion S63-4. PubMed ID: 9690972
[TBL] [Abstract][Full Text] [Related]
3. Do we need another atypical antipsychotic?
Kasper S
Eur Neuropsychopharmacol; 2008 Aug; 18 Suppl 3():S146-52. PubMed ID: 18511242
[TBL] [Abstract][Full Text] [Related]
4. Long-term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia. The Sertindole Study Group.
Daniel DG; Wozniak P; Mack RJ; McCarthy BG
Psychopharmacol Bull; 1998; 34(1):61-9. PubMed ID: 9564200
[TBL] [Abstract][Full Text] [Related]
5. Sertindole for the treatment of schizophrenia.
Azorin JM; Kaladjian A; Fakra E; Adida M
Expert Opin Pharmacother; 2010 Dec; 11(18):3053-64. PubMed ID: 21080854
[TBL] [Abstract][Full Text] [Related]
6. Sertindole in the treatment of psychosis in schizophrenia: efficacy and safety.
Tamminga CA; Mack RJ; Granneman GR; Silber CJ; Kashkin KB
Int Clin Psychopharmacol; 1997 Feb; 12 Suppl 1():S29-35. PubMed ID: 9179641
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
[TBL] [Abstract][Full Text] [Related]
8. Novel pharmacological approaches to the treatment of schizophrenia.
Fink-Jensen A
Dan Med Bull; 2000 Jun; 47(3):151-67. PubMed ID: 10913983
[TBL] [Abstract][Full Text] [Related]
9. Drug safety and efficacy evaluation of sertindole for schizophrenia.
Karamatskos E; Lambert M; Mulert C; Naber D
Expert Opin Drug Saf; 2012 Nov; 11(6):1047-62. PubMed ID: 22992213
[TBL] [Abstract][Full Text] [Related]
10. Atypical antipsychotics: mechanism of action.
Seeman P
Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
[TBL] [Abstract][Full Text] [Related]
11. Antipsychotic safety and efficacy concerns.
Meyer JM
J Clin Psychiatry; 2007; 68 Suppl 14():20-6. PubMed ID: 18284274
[TBL] [Abstract][Full Text] [Related]
12. [Sertindol, a new atypical neuroleptic drug: improved perspectives for schizophrenic patients].
Psychiatr Prax; 1997 Nov; 24(6 Suppl Das Atypis):1-4. PubMed ID: 9431363
[No Abstract] [Full Text] [Related]
13. Sertindole: new drug. Another "atypical" neuroleptic; QT prolongation.
Prescrire Int; 2007 Apr; 16(88):59-62. PubMed ID: 17458045
[TBL] [Abstract][Full Text] [Related]
14. Course of recovery of cognitive impairment in patients with schizophrenia: a randomised double-blind study comparing sertindole and haloperidol.
Gallhofer B; Jaanson P; Mittoux A; Tanghøj P; Lis S; Krieger S
Pharmacopsychiatry; 2007 Nov; 40(6):275-86. PubMed ID: 18030652
[TBL] [Abstract][Full Text] [Related]
15. [Sertindol, a new atypical neuroleptic drug: improved perspectives for schizophrenic patients].
Fortschr Neurol Psychiatr; 1997 Nov; 65(11 Suppl Das Atypis):1-4. PubMed ID: 9431350
[No Abstract] [Full Text] [Related]
16. Sertindole in treating schizophrenia.
Hosp Med; 1998 Feb; 59(2):165. PubMed ID: 9797900
[No Abstract] [Full Text] [Related]
17. The Sertindole Cohort Prospective (SCoP) study: rationale, design and methodology.
Peuskens J; Tanghøj P; Mittoux A;
Pharmacoepidemiol Drug Saf; 2008 May; 17(5):425-33. PubMed ID: 18384186
[TBL] [Abstract][Full Text] [Related]
18. Atypical antipsychotic drugs: current issues of safety and efficacy in the management of schizophrenia.
Vohora D
Curr Opin Investig Drugs; 2007 Jul; 8(7):531-8. PubMed ID: 17659473
[TBL] [Abstract][Full Text] [Related]
19. The European Post-marketing Observational Serdolect (EPOS) Project: increasing our understanding of schizophrenia therapy.
Wehnert A
Int Clin Psychopharmacol; 1998 Mar; 13 Suppl 3():S27-30. PubMed ID: 9690967
[TBL] [Abstract][Full Text] [Related]
20. Sertindole in schizophrenia: efficacy and safety issues.
Muscatello MR; Bruno A; Micali Bellinghieri P; Pandolfo G; Zoccali RA
Expert Opin Pharmacother; 2014 Sep; 15(13):1943-53. PubMed ID: 25084209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
